2021
HIV care using differentiated service delivery during the COVID‐19 pandemic: a nationwide cohort study in the US Department of Veterans Affairs
McGinnis KA, Skanderson M, Justice AC, Akgün KM, Tate JP, King JT, Rentsch CT, Marconi VC, Hsieh E, Ruser C, Kidwai‐Khan F, Yousefzadeh R, Erdos J, Park LS. HIV care using differentiated service delivery during the COVID‐19 pandemic: a nationwide cohort study in the US Department of Veterans Affairs. Journal Of The International AIDS Society 2021, 24: e25810. PMID: 34713585, PMCID: PMC8554215, DOI: 10.1002/jia2.25810.Peer-Reviewed Original ResearchConceptsVeterans AffairsClinic visitsCohort studyVL testARV coverageCOVID-19 pandemicVeterans Aging Cohort StudyHIV healthcare deliveryNationwide cohort studyAging Cohort StudyViral load testsDifferentiated service deliveryHealthcare deliveryHIV careMost patientsPharmacy recordsVL testingCalendar periodHealthcare encountersOverall healthARVVirtual healthcareVirtual visitsVisitsService delivery
2018
Brief Report
Yanik EL, Hernández-Ramírez RU, Qin L, Lin H, Leyden W, Neugebauer RS, Horberg MA, Moore RD, Mathews WC, Justice AC, Hessol NA, Mayor AM, Gill MJ, Brooks JT, Sun J, Althoff KN, Engels EA, Silverberg MJ, Dubrow R. Brief Report. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 78: 499-504. PMID: 29771785, PMCID: PMC6037538, DOI: 10.1097/qai.0000000000001719.Peer-Reviewed Original ResearchConceptsMelanoma incidenceAntiretroviral therapyGeneral populationMelanoma riskNorth American AIDS Cohort CollaborationRelationship of immunosuppressionWhite general populationHIV RNA levelsStandardized incidence ratiosCutaneous melanoma incidenceUltraviolet B exposureHigher melanoma incidenceHigh UVB exposureCohort CollaborationSkin surveillanceCD4 countHIV RNAImmune dysfunctionIncidence ratiosCox regressionHIV replicationRisk factorsCalendar periodWhite raceClinical care
2017
Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies
Collaboration T, Trickey A, May M, Vehreschild J, Obel N, Gill M, Crane H, Boesecke C, Patterson S, Grabar S, Cazanave C, Cavassini M, Shepherd L, Monforte A, van Sighem A, Saag M, Lampe F, Hernando V, Montero M, Zangerle R, Justice A, Sterling T, Ingle S, Sterne J. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. The Lancet HIV 2017, 4: e349-e356. PMID: 28501495, PMCID: PMC5555438, DOI: 10.1016/s2352-3018(17)30066-8.Peer-Reviewed Original ResearchConceptsInitiation of ARTAntiretroviral therapyART initiationCause mortalityHazard ratioLife expectancyCalendar periodCause-specific mortality hazard ratiosYears of ARTFirst yearHIV-1 cohortToxic antiretroviral drugsCombination antiretroviral therapyHIV-positive patientsCD4 cell countManagement of comorbiditiesMortality hazard ratioUK Medical Research CouncilHealth care plannersMedical Research CouncilEDCTP2 programmeCohort studyViral loadAntiretroviral drugsYear survival